Older adults with cancer heterogeneously experience health care, treatment, and symptoms.
Geriatric assessment (GA) offers a comprehensive evaluation of an older individual's health …

Multiple myeloma (MM) is an incurable blood cancer that primarily affects older adults.
Several frailty tools have been developed to address the heterogeneity of aging in this …

Background Selinexor combined with dexamethasone has shown activity in patients with
heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral …

In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple
myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved …

Multiple myeloma (MM) is a cancer of older adults and those who are more frail are at high
risk of poor outcomes. Current tools for identifying and categorizing frail patients are often …

As the treatment landscape continues to evolve towards the application of precision
medicine in multiple myeloma (MM), there is a clear need to identify those patients who are …

The literature is limited regarding outcomes in older adults and frail patients receiving BCMA-
directed chimeric antigen receptor T cell therapy (CAR-T) for relapsed or refractory multiple …

Multiple myeloma (MM) is primarily a disease of older patients. Until recently, geriatric
aspects in the context of MM have been poorly investigated. Treatment outcomes for …

Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we
dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for …

Importance Immune checkpoint inhibitors (ICIs) are part of standard of care for patients with
many advanced solid tumors. Patients with poor performance status or organ dysfunction …